Table 2_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Table 1_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …”

Table 3_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …”

Table 7_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …”

Supplementary file 2_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period... by Wubing Cao (20821589)

“…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …”

Table 1_Cancer-associated fibroblasts gene signature: a novel approach to survival prediction and immunotherapy guidance in colon cancer.docx by Wenbing Zhang (152972)

“…The nomogram further effectively predicted the prognosis of COAD patients, with low-risk patients having a better prognosis. A higher immune infiltration rate and lower IC50 values of anticancer drugs were significant in the high-risk group. …”

Table 2_Cancer-associated fibroblasts gene signature: a novel approach to survival prediction and immunotherapy guidance in colon cancer.xlsx by Wenbing Zhang (152972)

“…The nomogram further effectively predicted the prognosis of COAD patients, with low-risk patients having a better prognosis. A higher immune infiltration rate and lower IC50 values of anticancer drugs were significant in the high-risk group. …”

Image 1_Cancer-associated fibroblasts gene signature: a novel approach to survival prediction and immunotherapy guidance in colon cancer.tif by Wenbing Zhang (152972)

“…The nomogram further effectively predicted the prognosis of COAD patients, with low-risk patients having a better prognosis. A higher immune infiltration rate and lower IC50 values of anticancer drugs were significant in the high-risk group. …”

Table 1_Body Mass Index mediates the associations between dietary approaches to stop hypertension and obstructive sleep apnea among U.S. adults.docx by Songtao Li (186776)

“…</p>Conclusion<p>These findings suggested that DASH decreased OSA risk, which was possibly and partly mediated by BMI.…”

Image 1_Body Mass Index mediates the associations between dietary approaches to stop hypertension and obstructive sleep apnea among U.S. adults.tiff by Songtao Li (186776)

“…</p>Conclusion<p>These findings suggested that DASH decreased OSA risk, which was possibly and partly mediated by BMI.…”

Image 2_Body Mass Index mediates the associations between dietary approaches to stop hypertension and obstructive sleep apnea among U.S. adults.tiff by Songtao Li (186776)

“…</p>Conclusion<p>These findings suggested that DASH decreased OSA risk, which was possibly and partly mediated by BMI.…”

Table 2_Body Mass Index mediates the associations between dietary approaches to stop hypertension and obstructive sleep apnea among U.S. adults.docx by Songtao Li (186776)

“…</p>Conclusion<p>These findings suggested that DASH decreased OSA risk, which was possibly and partly mediated by BMI.…”